{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 68fb1748-eeb4-497a-95e8-3175420d503a --><h2>Update</h2><!-- end field 68fb1748-eeb4-497a-95e8-3175420d503a -->","summary":null,"htmlStringContent":"<!-- begin item 2c05e36c-42a4-4fd2-8ad7-915e1f43c436 --><!-- end item 2c05e36c-42a4-4fd2-8ad7-915e1f43c436 -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"33486424-9caa-5c04-a153-c524f9abaabb","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 67b9457c-16ac-4717-9da1-f509e454db2a --><h3>New evidence</h3><!-- end field 67b9457c-16ac-4717-9da1-f509e454db2a -->","summary":null,"htmlStringContent":"<!-- begin item c69d3662-5f80-4cb3-b703-881906183f36 --><!-- begin field 2e67d44f-7fd1-40c5-a900-9b5e1e853351 --><h3>Evidence-based guidelines</h3><!-- end field 2e67d44f-7fd1-40c5-a900-9b5e1e853351 --><!-- begin field eabe8f4e-86c6-46bc-97dc-bb9754154db3 --><p>No new guidelines published since 1 September 2019.</p><!-- end field eabe8f4e-86c6-46bc-97dc-bb9754154db3 --><!-- begin field 1bfbad03-9b11-461e-92f7-6b12f64f13d3 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 1bfbad03-9b11-461e-92f7-6b12f64f13d3 --><!-- begin field e766c487-fdf5-4407-b0c0-da4dd9ce1179 --><p>No new HTAs since 1 September 2019.</p><!-- end field e766c487-fdf5-4407-b0c0-da4dd9ce1179 --><!-- begin field f87ef103-574c-4875-9e53-a81dedfe6935 --><h3>Economic appraisals</h3><!-- end field f87ef103-574c-4875-9e53-a81dedfe6935 --><!-- begin field 2542a5a3-b220-4b74-ba1b-dc6e9b88a991 --><p>No new economic appraisals relevant to England since 1 September 2019.</p><!-- end field 2542a5a3-b220-4b74-ba1b-dc6e9b88a991 --><!-- begin field f9721ae9-4337-4eb0-8080-8090f2b167a2 --><h3>Systematic reviews and meta-analyses</h3><!-- end field f9721ae9-4337-4eb0-8080-8090f2b167a2 --><!-- begin field b6fdbe4c-d606-4ab5-8cf6-23de0606186d --><p>No new systematic reviews or meta-analyses since 1 September 2019.</p><!-- end field b6fdbe4c-d606-4ab5-8cf6-23de0606186d --><!-- begin field 53abe036-6d59-4486-bed4-9e9677885af3 --><h3>Primary evidence</h3><!-- end field 53abe036-6d59-4486-bed4-9e9677885af3 --><!-- begin field 3b39c1e5-0aba-4986-8cd2-63e59881e774 --><ul><li>Harrison, P.J., Colbourne, L., Luciano, S. (2021) <em>Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes.</em> British Journal of Psychiatry. <a href=\"http://www.cambridge.org/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"02d191b5-ded8-48c6-af64-acaa00fe925c\">www.cambridge.org</a> [<a href=\"https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/abs/incidence-of-neurodegenerative-and-cerebrovascular-diseases-associated-with-antihypertensive-drug-classes/F9BDF21B6305CAE266B9DC8377E924D6\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"2e1d872b-e3eb-4911-bdb7-acaa00fe925c\">Abstract</a>]</li></ul><!-- end field 3b39c1e5-0aba-4986-8cd2-63e59881e774 --><!-- end item c69d3662-5f80-4cb3-b703-881906183f36 -->","subChapters":[]},{"id":"219afd01-4e54-59dd-834b-d7179bd07ead","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 3fb3c5e8-153c-413c-b81d-3be2099671dc --><h3>New policies</h3><!-- end field 3fb3c5e8-153c-413c-b81d-3be2099671dc -->","summary":null,"htmlStringContent":"<!-- begin item f27054a2-9f08-42f5-bdc9-ebfca5767cee --><!-- begin field ae91dde5-aca6-4267-aa2a-05d8cce72238 --><p>No new national policies or guidelines since 1 September 2019.</p><!-- end field ae91dde5-aca6-4267-aa2a-05d8cce72238 --><!-- end item f27054a2-9f08-42f5-bdc9-ebfca5767cee -->","subChapters":[]},{"id":"ad0e0238-b5d3-58f7-956b-9e7851170dc9","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 54587fea-5f8f-42f8-a30c-7f9af6f6e399 --><h3>New safety alerts</h3><!-- end field 54587fea-5f8f-42f8-a30c-7f9af6f6e399 -->","summary":null,"htmlStringContent":"<!-- begin item 71bae9f4-f001-491e-9ada-2f0f1d4f3e73 --><!-- begin field 7a7f8d9a-b85f-4f3b-af7b-c56f6008cb6a --><p>No new safety alerts since 1 September 2019.</p><!-- end field 7a7f8d9a-b85f-4f3b-af7b-c56f6008cb6a --><!-- end item 71bae9f4-f001-491e-9ada-2f0f1d4f3e73 -->","subChapters":[]},{"id":"fdda0706-3d4d-5d80-8a39-892df6e9442b","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field e224163e-874f-4c9e-9f8c-4f194ce60704 --><h3>Changes in product availability</h3><!-- end field e224163e-874f-4c9e-9f8c-4f194ce60704 -->","summary":null,"htmlStringContent":"<!-- begin item c0e700f0-a716-4e1b-ad8b-83528451030f --><!-- begin field d373dd99-ab7f-4830-b160-5a567ded04c3 --><p>No changes in product availability since 1 September 2019.</p><!-- end field d373dd99-ab7f-4830-b160-5a567ded04c3 --><!-- end item c0e700f0-a716-4e1b-ad8b-83528451030f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}